Piotr Galecki

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8352836/publications.pdf

Version: 2024-02-01

122 papers	4,532 citations	172443 29 h-index	110368 64 g-index
132 all docs	132 docs citations	132 times ranked	6334 citing authors

#	Article	IF	Citations
1	A review on the oxidative and nitrosative stress (O&NS) pathways in major depression and their possible contribution to the (neuro)degenerative processes in that illness. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2011, 35, 676-692.	4.8	960
2	Depression and sickness behavior are Janus-faced responses to shared inflammatory pathways. BMC Medicine, 2012, 10, 66.	5.5	479
3	The interplay between inflammation, oxidative stress, DNA damage, DNA repair and mitochondrial dysfunction in depression. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2018, 80, 309-321.	4.8	206
4	Lipid peroxidation and antioxidant protection in patients during acute depressive episodes and in remission after fluoxetine treatment. Pharmacological Reports, 2009, 61, 436-447.	3.3	183
5	The expression of genes encoding for COX-2, MPO, iNOS, and sPLA2-IIA in patients with recurrent depressive disorder. Journal of Affective Disorders, 2012, 138, 360-366.	4.1	129
6	Shared metabolic and immune-inflammatory, oxidative and nitrosative stress pathways in the metabolic syndrome and mood disorders. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2017, 78, 34-50.	4.8	126
7	The anti-inflammatory mechanism of antidepressants â€“ SSRIs, SNRIs. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2018, 80, 291-294.	4.8	126
8	Inflammatory theory of depression. Psychiatria Polska, 2018, 52, 437-447.	0.5	117
9	The Neuro-Immune Pathophysiology of Central and Peripheral Fatigue in Systemic Immune-Inflammatory and Neuro-Immune Diseases. Molecular Neurobiology, 2016, 53, 1195-1219.	4.0	115
10	Oxidative stress parameters after combined fluoxetine and acetylsalicylic acid therapy in depressive patients. Human Psychopharmacology, 2009, 24, 277-286.	1.5	109
11	Nitrosative Stress, Hypernitrosylation, and Autoimmune Responses to Nitrosylated Proteins: New Pathways in Neuroprogressive Disorders Including Depression and Chronic Fatigue Syndrome. Molecular Neurobiology, 2017, 54, 4271-4291.	4.0	82
12	Depression and ways of coping with stress: A preliminary study. Medical Science Monitor, 2013, 19, 1050-1056.	1.1	71
13	Mechanisms Underlying Neurocognitive Dysfunctions in Recurrent Major Depression. Medical Science Monitor, 2015, 21, 1535-1547.	1.1	70
14	The levels of 7,8-dihydrodeoxyguanosine (8-oxoG) and 8-oxoguanine DNA glycosylase 1 (OGG1) â€“ A potential diagnostic biomarkers of Alzheimer's disease. Journal of the Neurological Sciences, 2016, 368, 155-159.	0.6	63
15	A narrative review on the similarities and dissimilarities between myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and sickness behavior. BMC Medicine, 2013, 11, 64.	5.5	62
16	Elevated Level of DNA Damage and Impaired Repair of Oxidative DNA Damage in Patients with Recurrent Depressive Disorder. Medical Science Monitor, 2015, 21, 412-418.	1.1	59
17	Singleâ€nucleotide polymorphisms and mRNA expression for melatonin synthesis rateâ€limiting enzyme in recurrent depressive disorder. Journal of Pineal Research, 2010, 48, 311-317.	7.4	53
18	Association between inducible and neuronal nitric oxide synthase polymorphisms and recurrent depressive disorder. Journal of Affective Disorders, 2011, 129, 175-182.	4.1	53

#	Article	IF	Citations
19	The molecular aspects of oxidative & nitrosative stress and the tryptophan catabolites pathway (TRYCATs) as potential causes of depression. Psychiatry Research, 2018, 262, 566-574.	3.3	46
20	Neurodevelopmental theory of depression. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2018, 80, 267-272.	4.8	44
21	Association between single nucleotide polymorphisms of TPH1 and TPH2 genes, and depressive disorders. Journal of Cellular and Molecular Medicine, 2018, 22, 1778-1791.	3.6	43
22	Toward Omics-Based, Systems Biomedicine, and Path and Drug Discovery Methodologies for Depression-Inflammation Research. Molecular Neurobiology, 2016, 53, 2927-2935.	4.0	40
23	Impact of oxidative/nitrosative stress and inflammation on cognitive functions in patients with recurrent depressive disorders. Medical Science Monitor, 2014, 20, 110-115.	1.1	38
24	The Immune Profile of Major Dysmood Disorder: Proof of Concept and Mechanism Using the Precision Nomothetic Psychiatry Approach. Cells, 2022, 11, 1183.	4.1	38
25	Cognitive functions in first-episode depression and recurrent depressive disorder. Psychiatria Danubina, 2015, 27, 38-43.	0.4	35
26	Role of MMP-2, MMP-7, MMP-9 and TIMP-2 in the development of recurrent depressive disorder. Journal of Affective Disorders, 2016, 205, 119-129.	4.1	33
27	Impact of Single Nucleotide Polymorphisms of Base Excision Repair Genes on DNA Damage and Efficiency of DNA Repair in Recurrent Depression Disorder. Molecular Neurobiology, 2017, 54, 4150-4159.	4.0	32
28	Variation of genes involved in oxidative and nitrosative stresses in depression. European Psychiatry, 2018, 48, 38-48.	0.2	32
29	miR-200a-3p modulates gene expression in comorbid pain and depression: Molecular implication for central sensitization. Brain, Behavior, and Immunity, 2019, 82, 230-238.	4.1	32
30	Affective symptoms in schizophrenia are strongly associated with neurocognitive deficits indicating disorders in executive functions, visual memory, attention and social cognition. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2018, 80, 168-176.	4.8	31
31	Functional Polymorphism of Cyclooxygenase-2 Gene (Gâ€“765C) in Depressive Patients. Neuropsychobiology, 2010, 62, 116-120.	1.9	30
32	Analysis of two polymorphisms of the manganese superoxide dismutase gene (Ile-58Thr and Ala-9Val) in patients with recurrent depressive disorder. Psychiatry Research, 2010, 179, 43-46.	3.3	30
33	Myeloperoxidase gene expression and cognitive functions in depression. Advances in Medical Sciences, 2015, 60, 1-5.	2.1	30
34	Polyunsaturated fatty acids and inflammatory markers in major depressive episodes during pregnancy. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2018, 80, 273-278.	4.8	30
35	An immune gate of depression â€“ Early neuroimmune development in the formation of the underlying depressive disorder. Pharmacological Reports, 2019, 71, 1299-1307.	3.3	30
36	Autobiographical memory dysfunctions in depressive disorders. Psychiatry and Clinical Neurosciences, 2016, 70, 100-108.	1.8	29

#	Article	IF	Citations
37	The role of MMP genes in recurrent depressive disorders and cognitive functions. Acta Neuropsychiatrica, 2016, 28, 221-231.	2.1	29
38	Is there a link between TNF gene expression and cognitive deficits in depression?. Acta Biochimica Polonica, 2017, 64, 65-73.	0.5	29
39	Inflammatory versus Anti-Inflammatory Profiles in Major Depressive Disordersâ€"The Role of IL-17, IL-21, IL-23, IL-35 and Foxp3. Journal of Personalized Medicine, 2021, 11, 66.	2.5	29
40	An inducible nitric oxide synthase polymorphism is associated with the risk of recurrent depressive disorder. Neuroscience Letters, 2010, 486, 184-187.	2.1	28
41	Oxidant/antioxidant imbalance is an inherent feature of depression. BMC Psychiatry, 2015, 15, 71.	2.6	28
42	Association between single nucleotide polymorphisms of MUTYH, hOGG1 and NEIL1 genes, and depression. Journal of Affective Disorders, 2015, 184, 90-96.	4.1	28
43	Vascular endothelial growth factor gene (VEGFA) polymorphisms may serve as prognostic factors for recurrent depressive disorder development. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2013, 45, 117-124.	4.8	26
44	Eicosapentaenoic and docosahexaenoic acids have different effects on peripheral phospholipase A2 gene expressions in acute depressed patients. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2018, 80, 227-233.	4.8	25
45	The Influence of C3435T Polymorphism of the ABCB1 Gene on Genetic Susceptibility to Depression and Treatment Response in Polish Population - Preliminary Report. International Journal of Medical Sciences, 2015, 12, 974-979.	2.5	24
46	The importance of TCF4 gene in the etiology of recurrent depressive disorders. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2018, 80, 304-308.	4.8	23
47	Expression and Activity of Metalloproteinases in Depression. Medical Science Monitor, 2016, 22, 1334-1341.	1.1	22
48	How to Construct a Bottom-Up Nomothetic Network Model and Disclose Novel Nosological Classes by Integrating Risk Resilience and Adverse Outcome Pathways with the Phenome of Schizophrenia. Brain Sciences, 2020, 10, 645.	2.3	22
49	Decreased expression level of BER genes in Alzheimer's disease patients is not derivative of their DNA methylation status. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2017, 79, 311-316.	4.8	20
50	Anti-Oxidative Effects of Melatonin Receptor Agonist and Omega-3 Polyunsaturated Fatty Acids in Neuronal SH-SY5Y Cells: Deciphering Synergic Effects on Anti-Depressant Mechanisms. Molecular Neurobiology, 2018, 55, 7271-7284.	4.0	20
51	Update on the neurodevelopmental theory of depression: is there any â€˜unconscious codeâ€™?. Pharmacological Reports, 2021, 73, 346-356.	3.3	20
52	ASMT gene expression correlates with cognitive impairment in patients with recurrent depressive disorder. Medical Science Monitor, 2014, 20, 905-912.	1.1	20
53	Vascular endothelial growth factor receptor 2 gene (KDR) polymorphisms and expression levels in depressive disorder. Journal of Affective Disorders, 2013, 147, 144-149.	4.1	19
54	COX-2 gene expression is correlated with cognitive function in recurrent depressive disorder. Psychiatry Research, 2014, 215, 488-490.	3.3	19

#	Article	IF	Citations
55	Mitochondrial DNA copy number, damage, repair and degradation in depressive disorder. World Journal of Biological Psychiatry, 2020, 21, 91-101.	2.6	19
56	Functional polymorphism of the myeloperoxidase gene (G-463A) in depressive patients. Acta Neuropsychiatrica, 2010, 22, 218-222.	2.1	18
57	Depressive, anxiety and hypomanic symptoms in schizophrenia may be driven by tryptophan catabolite (TRYCAT) patterning of IgA and IgM responses directed to TRYCATs. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2018, 80, 205-216.	4.8	17
58	Single-Nucleotide Polymorphisms of Genes Involved in Repair of Oxidative DNA Damage and the Risk of Recurrent Depressive Disorder. Medical Science Monitor, 2016, 22, 4455-4474.	1.1	16
59	Novel association between TGFA, TGFB1, IRF1, PTGS2 and IKBKB single-nucleotide polymorphisms and occurrence, severity and treatment response of major depressive disorder. PeerJ, 2020, 8, e8676.	2.0	16
60	Treatment-Resistant Depression in Polandâ€"Epidemiology and Treatment. Journal of Clinical Medicine, 2022, 11, 480.	2.4	16
61	Influence of Pharmacotherapy on Cognitive Functions in Depression: A Review of the Literature. Medical Science Monitor, 2015, 21, 3643-3651.	1.1	15
62	The Evolutionary Theory of Depression. Medical Science Monitor, 2017, 23, 2267-2274.	1.1	15
63	Relation between functional polymorphism of catalase gene (-262C>T) and recurrent depressive disorder. Neuroendocrinology Letters, 2009, 30, 357-62.	0.2	15
64	The role of interleukin genes in the course of depression. Open Medicine (Poland), 2016, 11, 41-48.	1.3	14
65	Polyunsaturated fatty acids levels and initial presentation of somatic symptoms induced by interferon-alpha therapy in patients with chronic hepatitis C viral infection. Nutritional Neuroscience, 2017, 20, 291-296.	3.1	14
66	BanI polymorphism of cytosolic phospholipase A2 gene and somatic symptoms in medication-free acute depressed patients. Prostaglandins Leukotrienes and Essential Fatty Acids, 2018, 136, 111-115.	2.2	12
67	Variation of genes encoding KAT1, AADAT and IDO1 as a potential risk of depression development. European Psychiatry, 2018, 52, 95-103.	0.2	12
68	Immune to happiness â€“ inflammatory process indicators and depressive personality traits. Archives of Medical Science, 2020, 16, 848-857.	0.9	12
69	Treatment-resistant depression - recommendations of the National Consultant in the field of psychiatry. Psychiatria Polska, 2021, 55, 7-21.	0.5	12
70	Single-nucleotide polymorphisms of uracil-processing genes affect the occurrence and the onset of recurrent depressive disorder. PeerJ, 2018, 6, e5116.	2.0	12
71	Working memory impairment as a common component in recurrent depressive disorder and certain somatic diseases. Neuroendocrinology Letters, 2013, 34, 436-45.	0.2	11
72	Is Interleukin 17 (IL-17) Expression A Common Point in the Pathogenesis of Depression and Obesity?. Journal of Clinical Medicine, 2020, 9, 4018.	2.4	9

#	Article	IF	Citations
73	Pharmacological treatment of a depressive episode and recurrent depressive disorder â€“ guidelines of the Polish Psychiatric Association and the National Consultant for Adult Psychiatry. Psychiatria Polska, 2021, 55, 235-259.	0.5	9
74	A Review of the Global Impact of the COVID-19 Pandemic on Public Mental Health, with a Comparison Between the USA, Australia, and Poland with Taiwan and Thailand. Medical Science Monitor, 2021, 27, e932220.	1.1	9
75	Brain Responses to Emotional Stimuli after Eicosapentaenoic Acid and Docosahexaenoic Acid Treatments in Major Depressive Disorder: Toward Personalized Medicine with Anti-Inflammatory Nutraceuticals. Journal of Personalized Medicine, 2020, 10, 283.	2.5	8
76	Preliminary Study of the Impact of Single-Nucleotide Polymorphisms of IL-1Î±, IL-1Î² and TNF-Î± Genes on the Occurrence, Severity and Treatment Effectiveness of the Major Depressive Disorder. Cellular and Molecular Neurobiology, 2020, 40, 1049-1056.	3.3	8
77	The Role of OXT, OXTR, AVP, and AVPR1a Gene Expression in the Course of Schizophrenia. Current Issues in Molecular Biology, 2022, 44, 336-349.	2.4	8
78	Inflammation and Cognition in Depression: A Narrative Review. Journal of Clinical Medicine, 2021, 10, 5859.	2.4	8
79	Cognitive Behavioral Therapy of Patients with Somatic Symptomsâ€”Diagnostic and Therapeutic Difficulties. Journal of Clinical Medicine, 2021, 10, 3159.	2.4	7
80	Serum KIBRA mRNA and Protein Expression and Cognitive Functions in Depression. Medical Science Monitor, 2016, 22, 152-160.	1.1	7
81	Inflammatory Markers and Episodic Memory Functioning in Depressive Disorders. Journal of Clinical Medicine, 2022, 11, 693.	2.4	7
82	Single nucleotide polymorphism of the KIBRA gene in recurrent depressive disorders. Neuroendocrinology Letters, 2010, 31, 97-102.	0.2	7
83	Is the JAK-STAT Signaling Pathway Involved in the Pathogenesis of Depression?. Journal of Clinical Medicine, 2022, 11, 2056.	2.4	7
84	Expression of PON1, PON2, PON3 and MPO Genes in Patients with Depressive Disorders. Journal of Clinical Medicine, 2022, 11, 3321.	2.4	7
85	Peripheral markers of inflammation, oxidative & nitrosative stress pathways and memory functions as a new target of pharmacotherapy in depression. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2018, 80, 167.	4.8	6
86	Bone Metabolism in Patients Treated for Depression. International Journal of Environmental Research and Public Health, 2020, 17, 4756.	2.6	6
87	Genetic Variations of Ionotropic Glutamate Receptor Pathways on Interferon-Î±-induced Depression in Patients with Hepatitis C Viral Infection. Brain, Behavior, and Immunity, 2021, 93, 16-22.	4.1	6
88	Expression of Selected Genes Involved in Neurogenesis in the Etiopathogenesis of Depressive Disorders. Journal of Personalized Medicine, 2021, 11, 168.	2.5	6
89	Characterizing polyubiquitinated forms of the neurodegenerative ubiquitin mutant <scp>UBB</scp>⁺¹. FEBS Letters, 2016, 590, 4573-4585.	2.8	4
90	Predictive Genetic Variations in the Kynurenine Pathway for Interferon-Î±-Induced Depression in Patients with Hepatitis C Viral Infection. Journal of Personalized Medicine, 2021, 11, 192.	2.5	4

#	Article	IF	Citations
91	Birth Month and Course of Recurrent Depressive Disorders in a Polish Population. Medical Science Monitor, 2018, 24, 4169-4174.	1.1	4
92	Estimation of CYP3A4*1B single nucleotide polymorphism in patients with recurrent Major Depressive Disorder. Molecular Genetics & Genomic Medicine, 2019, 7, e669.	1.2	3
93	iNOS gene expression correlates with cognitive impairment. Medical Science Technology, 0, 54, 16-21.	0.0	3
94	Thiol protein groups correlate with cognitive impairment in patients with recurrent depressive disorder. Neuroendocrinology Letters, 2013, 34, 780-6.	0.2	3
95	Cognitive functions and clinical features among diabetic patients in Polish population. Open Medicine (Poland), 2009, 4, 467-475.	1.3	2
96	The significance of microRNAs in the course of rDD. Pharmacological Reports, 2017, 69, 206-212.	3.3	2
97	Interleukin 17 and Treg â€“ a common pathomechanism and a new target of therapy in rheumatic diseases and depression. Reumatologia, 2018, 56, 201-202.	1.1	2
98	Preliminary investigation of two promoter region polymorphisms of the TNFA gene in patients with recurrent depressive disorder. Biomedical Reports, 2021, 15, 105.	2.0	2
99	Common pathomechanism of migraine and depression. Psychiatria Polska, 2023, 57, 405-419.	0.5	2
100	Personality Traits and Inflammation in Depressive Disorders. Journal of Clinical Medicine, 2022, 11, 1974.	2.4	2
101	Is NRXN1 Gene Expression an Important Marker of Treatment of Depressive Disorders? A Pilot Study. Journal of Personalized Medicine, 2021, 11, 637.	2.5	1
102	Neuroimmunology and (Epi)Genetics in Depressive Disorders. Journal of Personalized Medicine, 2021, 11, 670.	2.5	1
103	Suicide Risk Factors among Polish Adults Aged 65 or Older in 2000â€“2018 Compared with Selected Countries Worldwide. International Journal of Environmental Research and Public Health, 2021, 18, 9921.	2.6	1
104	The influence of CYP2C19*2 and CYP3A5*3 variants on the development of depression and effectiveness of therapy: A preliminary study. Biomedicine and Pharmacotherapy, 2021, 142, 112055.	5.6	1
105	The Heidenhain variant of Creutzfeldt-Jakob disease â€“ two patients initially misdiagnosed with dissociative disorder. Medical Science Technology, 0, 54, 112-119.	0.0	1
106	Difficulties in identifying emotional states in patients treated for depressive disorders compared to patients with selected somatic diseases. Medical Science Technology, 0, 54, 54-59.	0.0	1
107	Psychiatric Symptoms as Possible Brain Tumor Complications: A Case Report. Medical Science Technology, 0, 56, 73-77.	0.0	1
108	Does education level protect us from rapid ageing? Sirtuin expression versus age and level of education. Neuroendocrinology Letters, 2019, 40, 93-98.	0.2	1

#	Article	IF	Citations
109	Letter to the Editor. The Polish standard of teleconsultation in psychiatry. Psychiatria Polska, 2021, 55, 1473-1477.	0.5	1
110	Admission of a minor to a psychiatric hospital under Polish law. Part II.. Psychiatria Polska, 2021, 55, 599-605.	0.5	0
111	Admission of a minor to a psychiatric hospital under Polish law. Part I.. Psychiatria Polska, 2021, 55, 585-598.	0.5	0
112	Expertsâ€™ and national consultantsâ€™ recommendations regarding management of patients treated for migraine with comorbid depression. Diagnosis. Therapeutic strategies. Part 2.. Psychiatria Polska, 2021, , 1-18.	0.5	0
113	Expertsâ€™ and national consultantsâ€™ recommendations regarding management of patients treated for migraine with comorbid depression. Epidemiology. Pathomechanism. Comorbidity. Part 1.. Psychiatria Polska, 2021, , 1-14.	0.5	0
114	Legal and medical aspects associated with the use of direct coercion by emergency medical teams in the light of the applicable law.. Psychiatria Polska, 2021, 55, 757-767.	0.5	0
115	Results of the Stroop test among patients suffering from recurrent depressive disorders and organic depressive disorders. Medical Science Technology, 0, 54, 103-106.	0.0	0
116	The Role of Dvl3 in the Context of Neurodevelopmental Processes and Neuropsychiatric Disorders. Medical Science Technology, 0, 57, 95-103.	0.0	0
117	Treatment of Depression in Patients with Diabetes Mellitus: A Review. Medical Science Technology, 0, 57, 110-115.	0.0	0
118	The assessment of psychopathological symptoms and the course of schizophrenia depending on gender, duration of the disease, somatic comorbidity and suicide attempts. Pharmacotherapy in Psychiatry and Neurology, 2020, 36, 107-115.	0.1	0
119	Suicide â€“ definition of the phenomenon and prevalence in Poland. Polish Annals of Medicine, 0, , .	0.3	0
120	Documented persistent lack of cooperation during treatment of schizophrenia - recommendations of the National Consultant in Psychiatry. Psychiatria Polska, 2021, 55, 1183-1185.	0.5	0
121	Unusual magnetic resonance imaging of the head in manganese and ephedrone intoxication - a case report.. Polski Merkuriusz Lekarski, 2021, 49, 434-436.	0.3	0
122	Specificity of quality of life assessment in people with mental disorders. Psychiatria Polska, 2022, , 1-18.	0.5	0